Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (formerly named Shanghai Fosun Industrial Co., Ltd. hereinafter referred to as Fosun Pharmaceutical , ticker: 600196), was established in 1994 and listed on the Shanghai Stock Exchange in August 1998. It has now become a top listing enterprise in Chinese pharmaceutical industry. Since it was listed on the market in 1998, the net proits of Fosun Pharmaceutical have increased by 39 times in twelves years and the compound annual growth rate reached 39.59%. Net assets and net proit are listed front rank among the Chinese pharmaceutical companies.

Attaching great importance to innovation and development and possessing a national-level technology centre have enabled Fosun Pharmaceutical to attain leading market position for hepatic disease, diabetes medicine, gynecological medicines and clinical diagnosis products in China.

The outstanding market performance has become the study case for global top level business academies; the sustainable and secure development has made Fosun Pharmaceutical regarded as the benchmark for all the listed companies in China and occupied a predominant position in its industry steadily. The corporate brand was reputable in the medical health industry and capital market.

The company’ s innovation strategy is about paying equal attention to endogenetic growth and denotative expansion in both international and domestic markets. Therefore, with an aim to promote human health, Fosun Pharmaceutical will unswervingly abide by the “Innovation for Good Health” philosophy. To prospect, the company has forged a reputation as a competitive international pharmaceutical enterprise and its leading position in the pharmaceutical market in China today remains as secured and assured as ever.